Coronary Artery Disease ; Humans ; Osteoprotegerin

OBJECTIVEIn oder to treat periodontitis by using tissue engineering and gene engineering technology, the article established an transient expression system of bone marrow stromal cells (BMSC) modified by osteoprotegerin (OPG) gene and detected its expression using eukaryotic secreted expression pSecTag2/B-OPG plasmid.

METHODSBy solation and culture of BMSC in vitro, the identified recombined plasmid was transiently transfected into BMSC by Lipofectamine 2000 and OPG expression in BMSC was determined by RT-PCR and Western blot in 6 weeks.

RESULTSThe fragments of the recombinant plasmid digested with Hind III, EcoR I and BamH I and examined by 10 g/L agarose electrophoresis, were consistent with predicted size. The sequence of OPG was identical to the sequence provided by GeneBank [gi:33878056]. OPG transcribing in BMSC was confirmed by RT-PCR and OPG sustainable expressing in BMSC was detected by Western blot in 39 days.

CONCLUSIONThe transiently expression system of BMSC modified by OPG gene was successfully established.

Humans ; Mesenchymal Stromal Cells ; Osteoprotegerin ; Tissue Engineering ; Transfection

OBJECTIVETo explore certain principle of how osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL) take part in the periodontal tissues remodeling under the combined influence of inflammation and orthodontic force.

METHODSThe positive signals of OPG and OPGL mRNA were measured with in situ hybridzation after orthodontic tooth movement in the experimental periodontitis groups and control ones.

RESULTSThe OPG and OPGL mRNA expression intensity in the experimental group showed difference from control. All their optical density index reached a peak in day 2, respectively.

CONCLUSIONOPG and OPGL play important roles in the periodontal reconstruction induced by inflammation irritation and orthodontic force, and complex interaction could exist between the two factors.

Humans ; Osteoprotegerin ; Periodontitis ; RANK Ligand ; RNA, Messenger ; Tooth Movement Techniques

The purpose of this study was to evaluate the correlation between nicotine and the activity of bone forming cell. MG63 osteoblast-like cells were used for this study. Several factors were examined including the proliferation of cell, alkaline phosphatase activity, the formation of osteocalcin and osteoprotegerin, and the synthesis of its mRNA. MG63 osteoblast-like cells were incubated for 1, 2, 3 and 6 days with nicotine added to the culture medium in 1.0 micrometer, 1.0 mM, 2.5 mM, 5.0 mM, 7.5 mM, and 10.0 mM concentrations. The proliferation of MG63 osteoblast-like cells was temporarily activated at the low nicotine concentrations. At high concentrations (>5.0 mM), however, it was suppressed. Alkaline phosphatase activity was suppressed in a dose-dependent manner as the concentration of nicotine increased. Osteocalcin decreased in a dose-dependent manner at high nicotine concentrations of more than 7.5 mM and the same result was show when the osteoblasts were treated with low concentrations for longer than 3 days. There was a difference in the influence of nicotine on the synthesis of osteocalcin mRNA and formation of osteocalcin itself at 1 and 3 days. Generally, osteoprotegrin notably declined in all experimental groups. However, the level of its mRNA inc-reased at high nicotine concentrations of more than 7.5 mM after 3 days and more than 5.0 mM after 6 days.
Alkaline Phosphatase ; Nicotine* ; Osteoblasts ; Osteocalcin* ; Osteoprotegerin* ; RNA, Messenger*

OBJECTIVETo investigate the exerted force in different phases of the female menstrual cycle, as well as the changes in estrogen (E2), osteocalcin (OCN), receptor activator of nuclear factor-kappa B ligand (RANKL), and osteoprotegerin (OPG) levels in the gingival crevicular fluid (GCF) during orthodontic tooth movement, to provide a theoretical basis for the selection of the best opportunity for efficient tooth movement.

METHODSTwelve women (aged 18 years to 28 years) with extracted first premolars had been selected. Six women in the group were randomly selected as the menstrual period group, whereas the remaining six were assigned to the ovulation period group. Right canines were retracted with 1.5 N NiTi close coil spring. GCF samples were collected prior to the force exertion experiments at 0 (T0), 15 (T1), 30 (T2), and 45 d (T3). The levels of E2, OCN, OPG and RANKL in GCF were measured by chemiluminescence and enzymelinked immunosorbent assay.

RESULTSThe E2 and OCN levels were significantly higher in the ovulation period group than in the menstrual period group (P < 0.05). No significant differences were found in RANKL and OPG levels between the two groups (P > 0.05). Finally, no significant difference was found in RANKL/OPG ratio between the two groups (P > 0.05).

CONCLUSIONExerted force on teeth during the menstrual period may promote rapid tooth movement.

Female ; Gingival Crevicular Fluid ; Humans ; Menstrual Cycle ; Osteoprotegerin ; RANK Ligand ; Tooth Movement Techniques

OBJECTIVETo investigate the immunolocalization of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG), and to explore the correlation between their expressions and activity of osteoclast during first mandibular molar eruption.

METHODSMouse mandibles dissected from postnatal day 1.5 to 14.5 were stained respectively for multinucleated osteoclasts using tartrate-resistant acid phosphatase (TRAP) staining, and RANKL and OPG protein expression was examined by immunohistochemical staining.

RESULTSThe two peak values of osteoclast/acreage in the occlusal and basal region were both observed on the P1.5 and P9.5; while the two peak values in the lateral region were on P3.5 and P9.5. During the mouse molar eruption, burst of osteoclastogenesis was associated with high expression of RANKL and low expression of OPG.

CONCLUSIONSRANKL and OPG could have a close relationship with the osteoclast activity and two developmental apexes were observed during the molar eruption. The occlusal movement was relatively stable, meanwhile the temporarily accelerative movement to the basal and lateral regions could occur.

Animals ; Mice ; Mice, Inbred BALB C ; Osteoprotegerin ; immunology ; metabolism ; RANK Ligand ; immunology ; metabolism ; Tooth Eruption ; immunology

OBJECTIVETo investigate the effects of 17beta-estradiol on the expression of alkaline phosphatase (ALP) and osteoprotegerin in human periodontal ligament cells.

METHODSHuman periodontal ligament cells (hPDLC) were obtained from periodontal tissue explants of teeth extracted for orthodontic treatment ALP activity was determined by PNPP, and OPG protein and corresponding mRNA levels were quantitatively detected by ELISA and RT-PCR RESULTS: ALP activity was significantly increased at 14 days and 21 days (P <0.05). 17beta-E2 of physiological concentration promoted secretion of OPG protein and expression of OPG mRNA (P <0.05). 17beta-E2 with high-dose showed no effect on OPG protein secretion and decrease OPG mRNA expression.

CONCLUSIONS17beta-E2 may have a positive impact on periodontium through promoting expression of ALP and OPG in hPDLC.

Alkaline Phosphatase ; metabolism ; Cells, Cultured ; Estradiol ; pharmacology ; Humans ; Osteoprotegerin ; metabolism ; Periodontal Ligament ; cytology ; drug effects ; metabolism

As the periodontal ligament cells show similar phenotype with osteoblasts, periodontal ligament cells are thought to play an important role in alveolar bone remodeling. According to recent studies, receptor activation of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) are expressed in periodontal ligament cells during tooth movement. Also periodontal ligament cells is known to play an important role in the progression of periodontal disease. This study was designed how the expression of RANKL and OPG in periodontal ligament cells was regulated by IL-1betain the concentration of 0.01~10 ng/ml. The results are as follows; 1. Periodontal ligament cells which stimulated by IL-1beta increased soluble RANKL synthesis by dose-dependent pattern in the concentration of 0.01~10 ng/ml. 2. IL-1betainduced mRANKL expression in dose-dependent manner in the concentration of 0.01~5 ng/ml. 3. mOPG expression was not to be influenced by IL-1beta. These results suggested that rat periodontal ligament cells could regulate osteoclastogenesis by stimulation of production of RANKL.
Animals ; Bone Remodeling ; Osteoblasts ; Osteoprotegerin ; Periodontal Diseases ; Periodontal Ligament ; Phenotype ; Rats* ; Tooth Movement

OBJECTIVE: To determine the serum levels of soluble osteoprotegerin (OPG), decoy receptor of receptor activator of nuclear factor kB ligand (RANKL), in patients with systemic lupus erythematosus (SLE) and to assess the its relationships with certain clinical manifestations. METHODS: Serum levels of OPG in 60 patients with SLE and 30 healthy controls were determined by enzyme-linked immunosorbent assay. At the time of serum sampling, clinical manifestations and lupus disease activity index (SLEDAI) were assessed. RESULTS: Serum levels of OPG in 60 patients with SLE were significantly higher than in 30 healthy controls (1,058+/-699 versus 806+/-113 pg/mL, p=0.008). Patients with active disease had higher levels of OPG levels than those with inactive disease (1,355+/-837 versus 760+/-113 pg/mL, p<0.001). Serum OPG levels correlated with SLEDAI (gamma=0.588, p<0.0001), anti-dsDNA antibody titers (gamma=0.337, p=0.009) and serum MCP-1 levels (gamma=0.485, p<0.0001). In particular, serum OPG levels were found to be significantly increased in patients with neurological manifestation compared to those without (1,504+/-1,152 versus 918+/-376 pg/mL, p=0.004). CONCLUSION: The results of this study suggest that serum OPG levels are increased in patients with SLE. Serum OPG has a role as marker for disease activity and its increased levels reflect the involvement of neurological manifestation.
Enzyme-Linked Immunosorbent Assay ; Humans ; Lupus Erythematosus, Systemic* ; Neurologic Manifestations ; Osteoprotegerin*

No abstract available.
Cardiovascular Diseases/*etiology ; Female ; Humans ; Male ; Osteoprotegerin/*blood ; *Renal Dialysis ; Renal Insufficiency, Chronic/*therapy ; *Vascular Stiffness